Hims & Hers Health Inc (HIMS US)
What are your thoughts on HIMS & HERS as a medium-term investment?
The Latest Q&A
Answer
Hi Scott,
HIMS is a U.S.-based telehealth company that provides direct-to-consumer access to medical consultations, prescriptions, and wellness products. It offers treatments for conditions like hair loss, erectile dysfunction, anxiety, depression, and weight loss, often through a subscription model. The company uses technology to personalize care and recently expanded into compounded weight-loss injections and at-home lab testing.
The company’s revenue has been growing at a rapid pace, rising from US $526.9 million in 2022, up 65% to US $872 million in 2023, and surging another 69% to reach US $1.48 billion in 2024. However, there is plenty of competition in this growing space from Teladoc Health, (TDOC US), to LifeMd Inc (LFMD US) and relatively new entrant Amazon (AMZN US).
- We are bullish on the sector medium but less certain of who will become the incumbent player in the years ahead, investors need to keep their fingers on the pulse here.
